N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}cyclopropanecarboxamide | 762297-60-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}cyclopropanecarboxamide
• 英文别名: N-{3-[1-(3-aminopropyl)4-piperidinyl]phenyl}cyclopropanecarboxamide；N-[3-[1-(3-aminopropyl)piperidin-4-yl]phenyl]cyclopropanecarboxamide
• CAS: 762297-60-9
• 化学式: C₁₈H₂₇N₃O
• 分子量: 301.432
• InChiKey: NQRPFYXJEKZZOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}cyclopropanecarboxamide 、 2,2-二苯基丙酸 生成 N-[3-(1-{3-[(2,2-DIPHENYLPROPANOYL)AMINO]PROPYL}-4-PIPERIDINYL)PHENYL]CYCLOPROPANECARBOXAMIDE
  参考文献：
  名称：

  Substituted alkyl amido piperidines

  摘要：

  本发明涉及选择性抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种制药组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种通过将本发明化合物的治疗有效量和药学上可接受的载体结合而制成的制药组合物。本发明还提供了一种制备制药组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体结合。本发明还提供了一种减轻受试者体重的方法，包括向受试者投与本发明化合物的有效量以减轻受试者的体重。本发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者投与本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。

  公开号：

  US07105544B2
• 作为产物：
  描述：

  在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 N-{3-[1-(3-aminopropyl)-4-piperidinyl]phenyl}cyclopropanecarboxamide
  参考文献：
  名称：

  Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists

  摘要：

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.086

文献信息

• SUBSTITUTED ALKYL AMIDO PIPERIDINES
  申请人：Marzabadi R. Mohammad

  公开号：US20060041139A9

  公开（公告）日：2006-02-23

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

  本发明涉及一种选择性抗黑色素浓缩激素-1（MCH1）受体的化合物。本发明提供一种制药组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供一种由本发明化合物的治疗有效量和药学上可接受的载体组合而成的制药组合物。本发明还提供一种制备制药组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。本发明还提供一种减轻受试者体重的方法，包括向受试者给予本发明化合物的有效量以减轻受试者的体重。本发明还提供一种治疗患有抑郁和/或焦虑症的受试者的方法，包括向受试者给予本发明化合物的有效量以治疗受试者的抑郁和/或焦虑症。
• EP1590326A4
  申请人：——

  公开号：EP1590326A4

  公开（公告）日：2008-04-30
• US7105544B2
  申请人：——

  公开号：US7105544B2

  公开（公告）日：2006-09-12
• US7199135B2
  申请人：——

  公开号：US7199135B2

  公开（公告）日：2007-04-03
• [EN] SUBSTITUTED ALKYL AMIDO PIPERIDINES<br/>[FR] PEPERIDINES AMIDO ALKYLE SUBSTITUES
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2004064764A2

  公开（公告）日：2004-08-05

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.